


=> d l15
 L15 HAS NO ANSWERS
 L15 STR



VAR G1=C/N
 VAR G2=O/S/N
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> s l15
 SAMPLE SEARCH INITIATED 14:21:10 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 9691 TO ITERATE

20.6% PROCESSED 2000 ITERATIONS 28 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 187920 TO 199720
 PROJECTED ANSWERS: 2015 TO 3411


L16 28 SEA SSS SAM L15

=> s l15 ful
 FULL SEARCH INITIATED 14:21:15 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 193383 TO ITERATE

100.0% PROCESSED 193383 ITERATIONS 2456 ANSWERS
 SEARCH TIME: 00.00.01

L17 2456 SEA SSS FUL L15

=> d l18
 L18 HAS NO ANSWERS
 L18 STR



VAR G1=C/N
 VAR G2=O/S/N
 REP G3=(1-3) A
 VAR G4=9/8/13/12
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> search l18
 ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
 ENTER SUBSET L# OR (END):l17
 ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
 FULL SUBSET SEARCH INITIATED 14:22:25 FILE 'REGISTRY'
 FULL SUBSET SCREEN SEARCH COMPLETED - 2456 TO ITERATE

100.0% PROCESSED 2456 ITERATIONS 24 ANSWERS
 SEARCH TIME: 00.00.01

L19 24 SEA SUB=L17 SSS FUL L18

=> fil caplus
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
214.10	618.18

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-10.14

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 14:22:29 ON 24 JAN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jan 2007 VOL 146 ISS 5
FILE LAST UPDATED: 23 Jan 2007 (20070123/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 119

L20 10 L19

=> d bib abs hitstr 1-10

L20 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1351110 CAPLUS

DN 144:88316

TI Preparation of azaindoles as inhibitors of p38 kinase

IN Mavunkel, Babu J.; Perumattam, John J.; Lu, Qing; Dugar, Sundeeep; Goyal, Bindu; Wang, Dan X.; Chakravarty, Sarvajit; Luedtke, Gregory R.; Nashashibi, Imad; Tester, Richland; Tan, Xuefei

PA USA



SO U.S. Pat. Appl. Publ., 83 pp., Cont.-in-part of U.S. Ser. No. 683,656.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005288299	A1	20051229	US 2005-107027	20050415
	US 2004176598	A1	20040909	US 2003-683656	20031009
PRAI	US 2002-417599P	P	20021009		
	US 2003-683656	A2	20031009		
OS	MARPAT 144:88316				
GI					



II

AB Title compds. [I; dotted line = optional double bond; 1 of Z1, Z2 = CQ, CR1Q, the other = CRR1, C(R1)2; Q = R1, WiCOXjY; W, X = (substituted) alkylene, alkenylene, alkynylene, heteroalkylene; i, j = 0, 1; Y = COR2, isostere; Z3 = NR7, O, S; Z4, Z5 = N, CH, CR3, or 1 of Z4, Z5 = C to which L1 is linked; ≥1 of Z4, Z5 = N; Z6 = N, CR5; L1, L2 = (substituted) alkylene, alkenylene, alkynylene, heteroalkylene; Cy = 1-2 (substituted) (fused) 3-7 membered ring(s); R1, R2, R5, R7 = H, R3; R3 = (substituted) alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, acyl, heteroacyl, aryl, heteroaryl, halo, etc.; R4 = R3, O, NCN, etc.; n = 0-2; m = 0-4; p, q = 0-2; p+k = 0-3], were prepared Thus, title compound (II) inhibited p38α with IC50 = 0.01 μM.


IT 872355-34-5P 872355-35-6P 872355-36-7P
872355-38-9P 872355-39-0P 872355-40-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azaindoles as inhibitors of p38 kinase)

RN 872355-34-5 CAPLUS

CN Piperazine, 1-[(4-fluorophenyl)methyl]-2,5-dimethyl-4-(1H-pyrrolo[3,2-b]pyridin-5-ylcarbonyl)-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872355-35-6 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-3-acetic acid, 5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-α-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872355-36-7 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-3-acetic acid, 5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-α-oxo-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872355-38-9 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-3-acetic acid, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-α-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872355-39-0 CAPLUS

CN Piperazine, 1-[(4-fluorophenyl)methyl]-4-[(6-methoxy-1H-pyrrolo[3,2-b]pyridin-5-yl)carbonyl]-2,5-dimethyl-, (2S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872355-40-3 CAPLUS

CN Piperazine, 1-[(6-chloro-1H-pyrrolo[3,2-b]pyridin-5-yl)carbonyl]-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 872355-03-8P 872355-04-9P 872355-05-0P
872355-37-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(preparation of azaindoles as inhibitors of p38 kinase)

RN 872355-03-8 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-3-acetamide, 5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N-methyl- α -oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872355-04-9 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-3-acetamide, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N-methyl- α -oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872355-05-0 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-3-acetamide, 5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N-methyl- α -oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872355-37-8 CAPLUS


CN 1H-Pyrrolo[3,2-b]pyridine-3-acetic acid, 6-chloro-5-[[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]- α -oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 872355-71-0P 872355-78-7P 872355-79-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of azaindoles as inhibitors of p38 kinase)
 RN 872355-71-0 CAPLUS
 CN 1H-Pyrrolo[3,2-b]pyridine-3-acetic acid, 6-chloro-5-[[2,5-dimethyl-1-piperazinyl]carbonyl]- α -oxo-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872355-78-7 CAPLUS
 CN Piperazine, 1-[(4-fluorophenyl)methyl]-4-[[6-methoxy-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[3,2-b]pyridin-5-yl]carbonyl]-2,5-dimethyl-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872355-79-8 CAPLUS
 CN 1H-Pyrrolo[3,2-b]pyridine-3-acetamide, 5-[[2,5-dimethyl-1-piperazinyl]carbonyl]-6-methoxy-N-methyl- α -oxo-1-[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

49



L20 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:817865 CAPLUS

DN 141:314351

TI Preparation of 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity

IN Chang, George; Didiuk, Mary Theresa; Finneman, Jari Ilmari; Garigipati, Ravi Shanker; Kelley, Ryan Michael; Perry, David Austen; Ruggeri, Roger Benjamin; Bechle, Bruce Michael

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 335 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004085401	A1	20041007	WO 2004-IB836	20040315	
	WO 2004085401	A8	20051201			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004224082	A1	20041007	AU 2004-224082	20040315	
	CA 2520405	A1	20041007	CA 2004-2520405	20040315	
	EP 1622872	A1	20060208	EP 2004-720668	20040315	
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008897	A	20060418	BR 2004-8897	20040315	
	CN 1795177	A	20060628	CN 2004-80014645	20040315	
	JP 2006521344	T	20060921	JP 2006-506369	20040315	
	US 2004204450	A1	20041014	US 2004-807838	20040323	
	NL 1025839	A1	20040930	NL 2004-1025839	20040326	
	NL 1025839	C2	20060906			
	NO 2005004989	A	20051216	NO 2005-4989	20051026	
US 2006122224	A1	20060608	US 2005-305874	20051215		
PRAI	US 2003-458274P	P	20030328			
	US 2004-536217P	P	20040114			
	WO 2004-IB836	A	20040315			
	US 2004-807838	A1	20040323			
OS	MARPAT 141:314351					
GI						

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = C; J = N or C, wherein when J = C, then the bond between J and X is a single or double bond, if J = N, then the bond between J and X is a single bond; R1 = Y, W-Z or W-Y; Y = (un)substituted, (un)saturated 3-8 membered ring (or bicyclic ring) optionally having 1-4 heteroatoms, or (un)substituted, (un)saturated 1-10 membered straight or branched carbon chain optionally substituted with 1-2 heteroatoms; W = carbonyl, thiocarbonyl, sulfinyl, or sulfonyl; Z = OY, SY, NHY or NY₂; R2 = (un)substituted, (un)saturated 1-6 membered alkyl or heteroalkyl chain; R3 = (un)substituted, (un)saturated alkyl or heteroalkyl chain; R4, R5, R6, and R7 independently = H, bond, nitro, etc.; or adjacent combinations of R4, R5, R6, and R7 may optionally be taken together to form (un)substituted, (un)saturated carbocycle or heterocyclic ring], and pharmaceutical compns. containing such compds. are prepared and disclosed as cholesteryl ester transfer

protein (cetp) inhibitors. Thus, e.g., II was prepared by reaction of 3,5-bistrifluoromethylbenzoyl chloride with 4-diazo-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid Et ester (preparation given) in di-Et ether. Methods for bioassaying compds. I are described (no data). The use of I to elevate certain plasma lipid levels, including high d. lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans is further disclosed.


IT 769128-78-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinoline and quinoxaline derivs. as cholesteryl ester transfer protein inhibitors)

RN 769128-78-1 CAPLUS

CN 1(2H)-Quinoxalinecarboxylic acid, 2-ethyl-3,4-dihydro-6,7-dimethyl-4-[[5-(trifluoromethyl)thieno[3,2-b]pyridin-6-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:417748 CAPLUS
DN 139:6858

TI Preparation of 1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides as GABAA
receptor ligands
IN Maynard, George D.; Ghosh, Manuka; O'Donnell, Christopher J.
PA Neurogen Corporation, USA
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003044018	A1	20030530	WO 2002-US37157	20021119
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2467542	A1	20030530	CA 2002-2467542	20021119
	AU 2002366092	A1	20030610	AU 2002-366092	20021119
	US 6673811	B1	20040106	US 2002-299199	20021119
	EP 1453831	A1	20040908	EP 2002-803679	20021119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014301	A	20041013	BR 2002-14301	20021119
	JP 2005516901	T	20050609	JP 2003-545655	20021119
PRAI	US 2001-333027P	P	20011119		
	WO 2002-US37157	W	20021119		
OS	MARPAT 139:6858				
GI					



I

AB Disclosed are 1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides (shown as I; variables defined below; e.g. 5-(1-Methylpiperidin-4-yloxy)-1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid pyridin-2-ylamide) that bind to the benzodiazepine site of GABAA receptors. Such compds. can be used to modulate ligand binding to GABAA receptors in vivo and in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Each of 120 examples of I was tested for binding to the benzodiazepine site of GABAA receptors and each has a K_i of $<4 \mu\text{M}$; preferred compds. exhibit K_i values of $<100 \text{ nM}$ and more preferred compds. exhibit K_i values of $<10 \text{ nM}$; individual values are not given. Although the methods of preparation are not claimed, 2 example preps. and characterization data for .apprx.120 examples of I are included. For I: R_1 , R_2 , and R_3 = H, halogen, halo(C1-C6)alkyl, hydroxy, cyano, amino, alkyl, alkoxy, mono- or di-(C1-C6)alkylamino, mono- or

di-(C1-C6)alkylamino(C1-C6)alkyl, -C(O)NR10R11, -C(O)OR10, and -OC(O)R10, -C(O)R10 (R10 and R11 = H, C1-C6 alkyl, Ph, phenyl(C1-C6)alkyl, pyridyl, or pyridyl(C1-C6)alkyl), haloalkoxy, alkenyl, alkynyl, hydroxyalkyl, -D-R20, -E-R35, -C1-C4alkyl-D-R20, -C1-C4alkyl-O-R20, -E-R20-G-R30, -E-L, -E-R20-L, J, -C(O)-L, or -C1-C4alkyl-J. D is -S(O)n-, -S(O)nNH-, -S(O)nNH2, -S(O)nNR30-, -NHC(O)-, -NHC(O)H, -NR30C(:O)-, -NR30C(:O)H, -NHS(O)n-, and -NR30S(O)n-; E and G = -NH-, -N(C1-C6alkyl)-, S, and O; each R20 and R30 = (C1-C8)alkyl, (C3-C8) cycloalkyl or (C3-C8)cycloalkyl(C1-C6)alkyl; each R35 = (C1-C8)straight, (C1-C8) branched, (C3-C8)cyclic alkyl or (C3-C8) cycloalkyl(C1-C6)alkyl; J and L = saturated, partially unsatd., and aromatic rings having 4-7 ring atoms, where

0,

1, or 2 of the ring atoms are O or N and the remaining ring atoms are C, where the rings are (un)substituted with ≥ 1 substituents. R4 is H, halogen, or hydroxy; Ar = aryl, arylalkyl, heteroarylalkyl or heteroaryl group; each n = 0, 1, or 2; addnl. details including provisos are given in the claims. A method using compds. I and autoradiog. is claimed for

determining


the presence or absence of GABAA receptor in a sample.

IT 533912-89-9P, 5-[2-(4-Methylpiperazin-1-yl)ethoxy]-1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid pyridin-2-ylamide 533912-91-3P, 5-[2-(4-Methylpiperazin-1-yl)ethoxy]-1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid (1-methyl-1H-pyrazol-3-yl)amide

RL: ARG (Analytical reagent use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate and anal. reagent; preparation of pyrrolopyridinecarboxamides as GABAA receptor ligands)


RN 533912-89-9 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-3-carboxamide, 5-[2-(4-methyl-1-piperazinyl)ethoxy]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 533912-91-3 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine-3-carboxamide, 5-[2-(4-methyl-1-piperazinyl)ethoxy]-N-(1-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L20 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:324914 CAPLUS

DN 137:379663

TI Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives

AU Wyatt, Paul G.; Allen, Michael J.; Chilcott, Josie; Foster, Alison; Livermore, David G.; Mordaunt, Jackie E.; Scicinski, Jan; Woollard, Patrick M.
 CS Department of Medicinal Chemistry, Medicines Research Centre, GlaxoSmithKline, Herts, Stevenage, SG1 2NY, UK
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(10), 1399-1404
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 137:379663
 AB Studies to discover novel, potent and selective oxytocin antagonists are reported. Combinatorial libraries designed to find novel replacements of fragments of oxytocin antagonist L-371,257, identified pyrimidine, thiazole, indole and benzofuran as potential alternatives to the benzoic acid moiety of L-371,257. Addnl. investigations identified indole and benzofuran derivs. with potent oxytocin antagonist activity.
 IT 475649-73-1
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation and structure activity relationship of benzofuran derivs. as oxytocin antagonists)
 RN 475649-73-1 CAPLUS
 CN Piperidine, 4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)-1-(1H-pyrrolo[3,2-b]pyridin-5-ylcarbonyl)- (9CI) (CA INDEX NAME)




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:157780 CAPLUS
 DN 136:216748
 TI Preparation of 1H-imidazopyridine derivatives as TNF and interleukin-1 production inhibitors
 IN Kato, Hideo; Sakaguchi, Jun; Izumi, Tomoyuki; Kato, Kenichi
 PA Hokuriku Seiyaku Co., Ltd., Japan
 SO PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016370	A1	20020228	WO 2001-JP7150	20010821
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT,				

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2003002890 A 20030108 JP 2001-248468 20010820
 AU 2001078790 A5 20020304 AU 2001-78790 20010821
 PRAI JP 2000-250874 A 20000822
 JP 2001-116240 A 20010416
 WO 2001-JP7150 W 20010821
 OS MARPAT 136:216748
 GI




AB The title compds. I [R1 is hydrogen, alkyl, cycloalkyl, or aryl; R2 is hydrogen or lower alkyl; R3 is a saturated nitrogenous heterocyclic group; m is an integer of 0 to 3; and ring A is, e.g., an (un)substituted thiophene ring, etc., (said thiophene ring is fused to the pyridine ring)] are prepared In an in vitro test using cells, 4-methyl-1-[2-(4-piperidyl)ethyl]-2-(2-pyrrolyl)-1H-imidazo[5,4-d]thieno[3,2-b]pyridine at 0.001 μ mol/L gave 73% inhibition of TNF- α production

IT 402566-81-8P 402566-91-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 1H-imidazopyridine derivs. as TNF and interleukin-1 production inhibitors)


RN 402566-81-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[(5-methyl-6-nitrothieno[3,2-b]pyridin-7-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 402566-91-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[(6-amino-5-methylthieno[3,2-b]pyridin-7-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:762989 CAPLUS

DN 135:318419

TI Synthesis of substituted bipiperidines and their use as H1 antagonists

IN Lawrence, Louise; Rigby, Aaron; Sangane, Hitesh; Springthorpe, Brian

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 160 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.


KIND

DATE


APPLICATION NO.

DATE

PI	WO 2001077101	A1	20011018	WO 2001-SE751	20010405
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2403012	A1	20011018	CA 2001-2403012	20010405
	EP 1274701	A1	20030115	EP 2001-920053	20010405
	EP 1274701	B1	20050629		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009922	A	20030218	BR 2001-9922	20010405
	CN 1433411	A	20030730	CN 2001-810683	20010405
	JP 2003530393	T	20031014	JP 2001-575574	20010405
	NZ 521543	A	20041029	NZ 2001-521543	20010405
	EP 1493743	A1	20050105	EP 2004-20599	20010405
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR				
	AT 298748	T	20050715	AT 2001-920053	20010405
	CN 1660839	A	20050831	CN 2004-10102245	20010405
	US 2002077337	A1	20020620	US 2001-827488	20010406
	US 6525070	B2	20030225		
	ZA 2002007700	A	20040102	ZA 2002-7700	20020925
	NO 2002004774	A	20021129	NO 2002-4774	20021003
	US 2004006080	A1	20040108	US 2003-341027	20030113
	US 6903115	B2	20050607		
	US 2004014783	A1	20040122	US 2003-436582	20030513
	HK 1051193	A1	20051028	HK 2003-103424	20030514
	US 2005171092	A1	20050804	US 2005-76773	20050310
PRAI	GB 2000-8626	A	20000408		
	GB 2000-19111	A	20000803		
	SE 2000-3664	A	20001011		
	CN 2001-810683	A3	20010405		
	EP 2001-920053	A3	20010405		
	WO 2001-SE751	W	20010405		
	US 2001-827488	A3	20010406		
	US 2003-341027	A1	20030113		
	US 2003-436582	A3	20030513		
OS	MARPAT 135:318419				
GI					



I



II

AB Title compds. I [q, s, t = 0 - 1; n, r = 0 - 5; m, p = 0 - 2; X = CH, C(O), O, S, S(O), S(O), N-; provided that when m and p are both 1 then X is not CH; Y = NHR₂, OH; T = C(O), C(S), S(O), CH₂; R₁ = H, alkyl, aryl, heterocyclyl; R₂, R₄₇ = H, alkyl, aryl-alkyl, CO-alkyl; R₃ = alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, thioaryl, thioheterocyclyl] were prepared. Examples include: data for over 600 compds., 4 solid oral dosage and 1 parenteral (general) formulations, a bioassay for Ca²⁺ flux, human eosinophil chemotaxis and H₁ antagonism. E.g., 4-(3,4-dichlorophenoxy)piperidine was alkylated with 1-(tert-butoxycarbonyl)-4-piperidone (1,2-dichloroethane, NaBH(OAc)₃, HOAc, 18 h, room temperature) to give an intermediate [1,4']bipiperidine. This intermediate was deprotected (DCM, TFA, 4 h, room temperature) and the

resulting

bipiperidine condensed with 3-methanesulfonylbenzoic acid (THF, PYBROP, (i-Pr)₂NEt, 18 h, room temperature) to give example compound II isolated as the acetate salt. I are used in the treatment of a chemokine (such as CCR3) or H₁ mediated disease state.


IT 367498-32-6P 367499-96-5P 367499-97-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; synthesis of substituted bipiperidines and use as H₁ antagonists)


RN 367498-32-6 CAPLUS

CN 1,4'-Bipiperidine, 4-(3,4-dichlorophenoxy)-1'-[[5-(trifluoromethyl)thieno[3,2-b]pyridin-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 367499-96-5 CAPLUS

CN 1,4'-Bipiperidine, 4-(4-chloro-2-methylphenoxy)-1'-[[5-(trifluoromethyl)thieno[3,2-b]pyridin-6-yl]carbonyl] - (9CI) (CA INDEX NAME)



RN 367499-97-6 CAPLUS

CN 1,4'-Bipiperidine, 4-(4-chloro-3-methylphenoxy)-1'-[[5-(trifluoromethyl)thieno[3,2-b]pyridin-6-yl]carbonyl] - (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:78383 CAPLUS

DN 134:163059

TI Substituted piperazinone derivatives and other oxoazaheterocyclyl compounds useful as factor Xa/IIa inhibitors

IN Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls, Heinz W.; He, Wei; Condon, Stephen M.; Davis, Roderick S.; Hanney, Barbara A.; Spada, Alfred P.; Burns, Christopher J.; Jiang, John Z.; Li, Aiwen; Myers, Michael R.; Lau, Wan F.; Poli, Gregory B.

PA Aventis Pharmaceuticals Products Inc., USA

SO PCT Int. Appl., 460 pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007436	A2	20010201	WO 2000-IB1156	20000726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

CA 2382755	A1	20010201	CA 2000-2382755	20000726
BR 2000013179	A	20020402	BR 2000-13179	20000726
EP 1208097	A2	20020529	EP 2000-951781	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200200225	T2	20020621	TR 2002-225	20000726
HU 200203375	A2	20021228	HU 2002-3375	20000726
JP 2003508353	T	20030304	JP 2001-512520	20000726
EE 200200045	A	20030616	EE 2002-45	20000726
AU 773227	B2	20040520	AU 2000-64628	20000726
NO 2002000214	A	20020402	NO 2002-214	20020115
BG 106340	A	20021031	BG 2002-106340	20020122
ZA 2002000543	A	20030623	ZA 2002-543	20020122
PRAI US 1999-363196	A	19990728		
WO 2000-IB1156	W	20000726		
OS MARPAT 134:163059				
GI				



AB The invention is directed to piperazinones I and their pharmaceutically acceptable salts, prodrugs, N-oxides, hydrates, and solvates [wherein A = CH or N; G1 and G2 = L1Cyl or L2Cy2; Cyl and Cy2 = (un)substituted aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, etc.; L1 = null, O, S, SO, SO2, or (un)substituted sulfamoyl, methylene, (alkyl)keto(alkyl), carbamoyl, etc.; L2 = null or linking group; R1, R1a, R2, R2a, R3, R3a, R4, R4a = independently H, carboxy, alkoxy, carbonyl, alkyl, (hetero)aryl, aralkyl, heteroarylalkyl, etc.; m and n = independently 0-2]. The compds. inhibit factor Xa (no data) and factor IIa, and thereby the production of thrombin, and are thus useful as anticoagulants in the treatment of a wide variety of conditions. The invention is also directed to pharmaceutical compns., synthetic intermediates, and a method of inhibiting factor Xa. Examples include the synthesis of approx. 1600 invention compds. and several hundred intermediates. For instance, condensation of 5-chloro-2-thienyloxyacetic acid with the corresponding N-benzyloxycarbonyl-protected piperazinone derivative (prepns. given), using DIPEA and TBTU in DMF, gave II.

IT 234102-19-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of piperazinone derivs. and other substituted oxoazaheterocyclyl compds. as factor Xa/IIa inhibitors)

RN 234102-19-3 CAPLUS


CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(5-chlorothieno[3,2-

b]pyridin-6-yl)methyl]- (9CI) (CA INDEX NAME)



L20 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:576158 CAPLUS
 DN 133:275852
 TI Identification of MK-944a: A Second Clinical Candidate from the Hydroxylaminepentanamide Isostere Series of HIV Protease Inhibitors
 AU Dorsey, Bruce D.; McDonough, Colleen; McDaniel, Stacey L.; Levin, Rhonda B.; Newton, Christina L.; Hoffman, Jacob M.; Darke, Paul L.; Zugay-Murphy, Joan A.; Emini, Emilio A.; Schleif, William A.; Olsen, David B.; Stahlhut, Mark W.; Rutkowski, Carrie A.; Kuo, Lawrence C.; Lin, Jiunn H.; Chen, I-W.; Michelson, Stuart R.; Holloway, M. Katharine; Huff, Joel R.; Vacca, Joseph P.
 CS Departments of Medicinal Chemistry Antiviral Research Drug Metabolism and Molecular Systems, Merck Research Laboratories, West Point, PA, 19486, USA
 SO Journal of Medicinal Chemistry (2000), 43(18), 3386-3399
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 133:275852
 AB Recent results from human clin. trials have established the critical role of HIV protease inhibitors in the treatment of acquired immune-deficiency syndrome (AIDS). However, the emergence of viral resistance, demanding treatment protocols, and adverse side effects have exposed the urgent need for a second generation of HIV protease inhibitors. The continued exploration of the authors hydroxylaminepentanamide (HAPA) transition-state isostere series of HIV protease inhibitors, which initially resulted in the identification of Crixivan (indinavir sulfate, MK-639, L-735,524), has now yielded MK-944a (L-756,423). This compound is potent, is selective, and competitively inhibits HIV-1 PR with a K_i value of 0.049 nM. It stops the spread of the HIVIIIb-infected MT4 lymphoid cells at 25.0-50.0 nM, even in the presence of α 1 acid glycoprotein, human serum albumin, normal human serum, or fetal bovine serum. MK-944a has a longer half-life in several animal models (rats, dogs, and monkeys) than indinavir sulfate and is currently in advanced human clin. trials.
 IT 298702-87-1P
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (identification of MK-944a as second clin. candidate from hydroxylaminepentanamide isostere series of HIV protease inhibitors with good bioavailability and pharmacokinetics and low toxicity in relation to antiviral resistance)
 RN 298702-87-1 CAPLUS
 CN D-erythro-Pentonamide, 2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[[[(1,1-dimethylethyl)amino]carbonyl]-4-(furo[3,2-b]pyridin-6-yl)methyl]-1-piperazinyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:384179 CAPLUS

DN 133:30741

TI Substituted piperazinone derivatives and other oxoazaheterocyclyl
compounds useful as factor Xa inhibitors

IN Ewing, William R.; Becker, Michael R.; Myers, Michael R.; Spada, Alfred P.

PA Aventis Pharmaceuticals Products Inc., USA

SO PCT Int. Appl., 219 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000032590	A1	20000608	WO 1999-US28074	19991124
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO 9937304	A1	19990729	WO 1999-US1682	19990127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2003529531	T	20031007	JP 2000-585232	19991124
PRAI	US 1998-110012P	A2	19981125		
	WO 1999-US1682	A2	19990127		
	US 1999-313611	A2	19990518		
	US 1999-363196	A2	19990728		
	US 1998-72707P	A2	19980127		
	WO 1999-US28074	W	19991124		
OS	MARPAT 133:30741				
GI					



I



II

AB The invention is directed to piperazinones I and their pharmaceutically acceptable salts, prodrugs, N-oxides, hydrates, and solvates [wherein R1 = H, alkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, alkoxy, aminoalkyl, CH2OZ, CH(CH3)OZ; R2 = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl, or heteroarylalkyl; R3 = H or Me; X = N or O; Z = lower alkyl or alkoxyalkyl; Cy1 = (un)substituted aryl, (un)substituted heteroaryl; Cy2 = (un)substituted aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, etc.]. The compds. inhibit factor Xa (no data), and thereby the production of thrombin, and are thus useful as anticoagulants in the treatment of a wide variety of conditions. The invention is also directed to pharmaceutical compns., synthetic intermediates, and a method of inhibiting factor Xa. Examples include the synthesis of approx. 780 invention compds., approx. 50 of which are also claimed, and several hundred intermediates. For instance, condensation of 5-chloro-2-thienyloxyacetic acid with the corresponding N-benzyloxycarbonyl-protected piperazinone derivative (prepn. given), using DIPEA and TBTU in DMF, gave the preferred title compound II.


IT 234102-19-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of piperazinone derivs. and other substituted oxoazaheterocyclyl compds. as factor Xa inhibitors)

RN 234102-19-3 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(5-chlorothiophen-2-yl)methyl]- (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:487215 CAPLUS

DN 131:130007
 TI Substituted piperazinone derivatives and other oxoazaheterocyclyl
 compounds useful as factor Xa inhibitors
 IN Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls,
 Heinz W.; He, Wei; Condon, Stephen M.; Davis, Roderick S.; Hanney, Barbara
 A.; Spada, Alfred P.; Burns, Christopher J.; Jiang, John Z.; Li, Aiwen;
 Myers, Michael R.; Lau, Wan F.; Poli, Gregory B.
 PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
 SO PCT Int. Appl., 300 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9937304	A1	19990729	WO 1999-US1682	19990127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9900607	A	19990727	ZA 1999-607	19990127
	CA 2319198	A1	19990729	CA 1999-2319198	19990127
	AU 9926533	A	19990809	AU 1999-26533	19990127
	AU 745425	B2	20020321		
	BR 9907300	A	20001024	BR 1999-7300	19990127
	EP 1051176	A1	20001115	EP 1999-906684	19990127
	EP 1051176	B1	20061122		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200002182	T2	20001221	TR 2000-200002182	19990127
	JP 2002501024	T	20020115	JP 2000-528286	19990127
	EE 200000435	A	20020215	EE 2000-435	19990127
	HU 200101810	A2	20020429	HU 2001-1810	19990127
	WO 2000032590	A1	20000608	WO 1999-US28074	19991124
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2003529531	T	20031007	JP 2000-585232	19991124
	NO 2000003808	A	20000926	NO 2000-3808	20000725
	BG 104633	A	20010330	BG 2000-104633	20000725
	US 2004102450	A1	20040527	US 2003-628093	20030725
PRAI	US 1998-72707P	A2	19980127		
	US 1998-110012P	A2	19981125		
	WO 1999-US1682	W	19990127		
	US 1999-313611	A2	19990518		
	US 1999-363196	A2	19990728		
	WO 1999-US28074	W	19991124		
OS	MARPAT 131:130007				
GI					



AB The invention is directed to oxoazaheterocyclyl compds. I and their pharmaceutically acceptable salts, prodrugs, N-oxides, hydrates, and solvates [wherein A = CH, N; G1, G2 = (independently) -L-Cy; L = various atomic and mol. linkers, including O, (un)substituted NH or S, alk(en/yn)ylene, etc., or their combinations; Cy = (un)substituted (hetero)aryl, cycloalk(en)yl; heterocyclyl, etc.; R = (independently) H, CO₂H, alkoxycarbonyl, (un)substituted carbamoyl, alkyl, (hetero)aryl, (hetero)aralkyl; or two geminal R groups = O or S; m, n = 0-2; with provisos]. The compds. inhibit factor Xa (no data), and thereby the production of thrombin, and are thus useful as anticoagulants in the treatment of a wide variety of conditions. The invention is also directed to pharmaceutical compns., synthetic intermediates, and a method of inhibiting factor Xa. Examples include the synthesis of approx. 780 compds. I, which are also claimed, and several hundred intermediates. For instance, sulfonamidation of 6-chlorobenzo[b]thiophene-2-sulfonyl chloride with 4-(2-oxopiperazin-1-ylmethyl)benzamidinium bistrifluoroacetate (preps. given) in CH₂Cl₂ in the presence of Et₃N gave title compound II.


IT 234102-19-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of piperazinone derivs. and other substituted oxoazaheterocyclyl compds. as factor Xa inhibitors)


RN 234102-19-3 CAPLUS

CN Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(5-chlorothieno[3,2-b]pyridin-6-yl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 16
 L6 HAS NO ANSWERS
 L6 STR



VAR G1=C/N
 VAR G2=O/S/N
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> s 16
 SAMPLE SEARCH INITIATED 14:01:06 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 8256 TO ITERATE

24.2% PROCESSED 2000 ITERATIONS 50 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 159674 TO 170566
 PROJECTED ANSWERS: 6350 TO 8674


L7 50 SEA SSS SAM L6

=> s 16 ful
 FULL SEARCH INITIATED 14:01:12 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 165556 TO ITERATE

100.0% PROCESSED 165556 ITERATIONS 6958 ANSWERS
 SEARCH TIME: 00.00.01

L8 6958 SEA SSS FUL L6

=> d l11
 L11 HAS NO ANSWERS
 L11 STR



VAR G1=C/N
 VAR G2=O/S/N
 REP G3=(1-3) A
 VAR G4=9/8/13/12
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 8
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> search l11
 ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
 ENTER SUBSET L# OR (END):l8
 ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
 FULL SUBSET SEARCH INITIATED 14:03:24 FILE 'REGISTRY'
 FULL SUBSET SCREEN SEARCH COMPLETED - 6958 TO ITERATE


100.0% PROCESSED 6958 ITERATIONS 293 ANSWERS
 SEARCH TIME: 00.00.01

L12. 293 SEA SUB=L8 SSS FUL L11

=> d scan

L12 293 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[3-[[[(3R)-3-hydroxy-1-pyrrolidinyl]oxoacetyl]-6-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl]carbonyl]-
 (9CI)
 MF C27 H29 F N4 O5

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 13:59:51 ON 24 JAN 2007)

FILE 'REGISTRY' ENTERED AT 14:00:19 ON 24 JAN 2007
ACTIVATE CC683656/A

L1 STR
L2 (173)SEA FILE=REGISTRY SSS FUL L1
L3 STR
L4 (39)SEA FILE=REGISTRY SSS FUL L3
L5 212 SEA FILE=REGISTRY L2 OR L4

L6 STRUC
L7 50 S L6
L8 6958 S L6 FUL

FILE 'CAPLUS' ENTERED AT 14:01:18 ON 24 JAN 2007
L9 861 S L8
L10 172 S L9 AND INFLAMMA?


FILE 'REGISTRY' ENTERED AT 14:01:43 ON 24 JAN 2007
L11 STRUC
L12 293 SEARCH L11 SSS SUB=L8 FUL

FILE 'CAPLUS' ENTERED AT 14:03:37 ON 24 JAN 2007
L13 59 S L12
L14 43 S L13 AND PY<2002

=> d bib abs hitstr 1

L14 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:935602 CAPLUS
DN 136:69741
TI Preparation of azaindoles as antitumor agents
IN Longo, Antonio; Brasca, Maria Gabriella; Orsini, Paolo; Traquandi, Gabriella; Pittala, Valeria; Vulpetti, Anna; Varasi, Mario; Pevarello, Paolo
PA Pharmacia & Upjohn S.p.A., Italy
SO PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098299	A1	20011227	WO 2001-EP6890	20010613 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6335342	B1	20020101	US 2000-597274	20000619
	CA 2411865	A1	20011227	CA 2001-2411865	20010613 <--
	AU 2001066079	A5	20020102	AU 2001-66079	20010613
	EP 1309590	A1	20030514	EP 2001-943522	20010613
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004501152	T	20040115	JP 2002-504255	20010613
	NZ 523002	A	20040924	NZ 2001-523002	20010613
	US 6486322	B2	20021126	US 2001-968042	20011002
	US 2003004350	A1	20030102		
PRAI	US 2000-597274	A	20000619		
	WO 2001-EP6890	W	20010613		
OS	MARPAT 136:69741				
GI					



AB The title 1H-pyrrolo[2,3-b]pyridines [I; R = H, halo, CN, etc.; R1 = H, alkyl; R2 = alkyl, aryl; R3 = H, CONR4R5, CO2R4, CONHOR4, SO2NHR4, alkylsulfonylaminocarbonyl, perfluorinated alkylsulfonylaminocarbonyl; R4, R5 = H, alkyl, aryl, etc.] or their pharmaceutically acceptable salts, useful for treating cell proliferative disorders associated with an altered cell cycle dependent kinase activity (no data given), were prepared Thus,

reacting phenylacetic acid with 1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde in the presence of Ac2O and Et3N afforded 44% I [R, R1 = H; R2 = Ph; R3 = CO2H].

IT 383869-91-8P 383869-93-0P 383870-60-8P

383870-64-2P 383871-25-8P 383871-27-0P

383872-04-6P 383872-06-8P 383872-52-4P


383872-55-7P 383872-92-2P 383872-94-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azaindoles as antitumor agents)


RN 383869-91-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-(3-amino-3-oxo-2-phenyl-1-propenyl)-1H-pyrrolo[2,3-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



=> d bib abs hit hitstr 38

L14 ANSWER 38 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:515227 CAPLUS
DN 113:115227
TI Polycyclic pyridines. Part 8. Synthesis of new primary, secondary and tertiary 3-aminothieno[2,3-b]pyridine-2-carboxamides by different pathways
AU Wagner, G.; Vieweg, H.; Leistner, S.; Boehm, N.; Krasselt, U.; Hanfeld, Vera; Prantz, J.; Grupe, Renate
CS Sekt. Biowiss., Karl-Marx-Univ., Leipzig, DDR-7010, Ger. Dem. Rep.
SO Pharmazie (1990), 45(2), 102-9
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
OS CASREACT 113:115227
GI



AB The treatment of 2-thioxo-1,2-dihydropyridine-3-carbonitriles with ClCH2CO2NR1R3 (R1, R2 = H, Me, Et) gave 3-aminothieno[2,3-b]pyridinecarboxylic acid amides I [R1 = H, Et, Me; R2 = H, Et, Bu, cyclohexyl, CH2CH2OH, CH2CO2H; R1R2 = (CH2)5; R3 = Me, Ph, 4-BrC6H4, 3-pyridyl, CONH2, etc; R4 = H, Me, CH2C6H4(CN)-4; R5 = Me, C6H4Cl-4, Ph, C6H4Br-4, furyl, naphthyl, OH). Some of the compds. thus prepared, e.g. I (R1 = R2 = R4 = H, R3 = Me, R5 = Ph) and I (R1 = R4 = H, R2 = CH2CH2OH, R3 = R5 = Me) showed activity as antiallergics in the passive cutaneous anaphylaxis test in rats.

SO Pharmazie (1990), 45(2), 102-9
CODEN: PHARAT; ISSN: 0031-7144


IT 56891-69-1P 67795-42-0P 72701-64-5P 94638-98-9P 115919-79-4P
115919-80-7P 115919-86-3P 119003-35-9P 119003-36-0P 119003-37-1P
119003-38-2P 119003-39-3P 128917-96-4P 128917-97-5P 128917-98-6P
128917-99-7P 128918-00-3P 128918-01-4P 128918-02-5P 128918-03-6P
128918-04-7P 128918-05-8P 128918-06-9P 128918-07-0P
128918-08-1P 128918-09-2P 128918-10-5P 128918-11-6P
128918-13-8P 128918-15-0P 128918-16-1P 128918-17-2P 128918-18-3P
128918-19-4P 128918-20-7P 128918-21-8P 128918-22-9P 128918-23-0P
128918-24-1P 128918-25-2P 128918-26-3P 128918-27-4P 128918-28-5P
128918-29-6P 128918-30-9P 128918-31-0P 128918-33-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


IT 128918-08-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 128918-08-1 CAPLUS

CN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-methyl-4-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)



=> d l4
 L4 HAS NO ANSWERS
 L4 STR



VAR G1=C/N
 VAR G2=O/S/N
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 1 8
 NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

=> s l4
 SAMPLE SEARCH INITIATED 13:28:37 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 9941 TO ITERATE

20.1% PROCESSED 2000 ITERATIONS 0 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 192845 TO 204795
 PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 ful
 FULL SEARCH INITIATED 13:28:42 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 199413 TO ITERATE


100.0% PROCESSED 199413 ITERATIONS 39 ANSWERS
 SEARCH TIME: 00.00.02

L6 39 SEA SSS FUL L4

=> d scan

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(4S)-hexahydro-1-(4-morpholinylsulfonyl)-3-oxo-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-3-methyl- (9CI)
 MF C25 H35 N5 O7 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):38

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(4S,7R)-hexahydro-2,4-d2-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl-2-d]amino]carbonyl]-3-methylbutyl]-3-methyl- (9CI)

MF C27 H30 D3 N5 O6 S

Absolute stereochemistry.




L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-[[[(4S,7R)-hexahydro-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]-2-oxoethyl]-3-methyl- (9CI)

MF C30 H37 N5 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Azepin-4-amine, 1-furo[3,2-b]pyridin-6-ylhexahydro-N-methyl-, (4S)-
 (9CI)
 MF C14 H19 N3 O

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[3,2-b]pyridine, 7-(hexahydro-1H-1,4-diazepin-1-yl)-5-phenyl- (9CI)
 MF C18 H19 N3 S
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzeneacetamide, N-[[[3-fluoro-4-[[2-[(hexahydro-1H-azepin-1-yl)carbonyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]-(9CI)
 MF C29 H27 F N4 O3 S2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[3,2-b]pyridine-3-carbonitrile, 2-(hexahydro-1H-azepin-1-yl)-(9CI)
 MF C14 H16 N4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-[[[(3S,4S,7R)-hexahydro-3-hydroxy-7-methyl-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]-2-oxoethyl]-3-methyl- (9CI)
 MF C30 H39 N5 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(4S,7R)-hexahydro-2,4-d2-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl-2-d]amino]carbonyl]-3-methylbutyl]- (9CI)
 MF C26 H28 D3 N5 O6 S

Absolute stereochemistry.




L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Azepin-3-amine, 1-furo[3,2-b]pyridin-6-ylhexahydro-, (3R)- (9CI)
 MF C13 H17 N3 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxamide, hexahydro-N-methyl-4-(5-phenylthieno[3,2-b]pyridin-7-yl)- (9CI)
 MF C20 H22 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Azepine-1-carboxylic acid, hexahydro-, (2S)-2-[5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethyl-1H-pyrrolo[3,2-b]pyridin-1-yl]butyl ester (9CI)
 MF C28 H34 F3 N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[hexahydro-1-[(1-oxido-2-pyridinyl)sulfonyl]-3-oxo-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-3-methyl- (9CI)
 MF C26 H31 N5 O7 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[1-[[[(4S,7R)-hexahydro-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]cyclohexyl]-3-methyl- (9CI)
 MF C28 H33 N5 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Azepin-4-amine, 1-furo[3,2-b]pyridin-6-ylhexahydro-, (4R)- (9CI)
 MF C13 H17 N3 O

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxamide, N-ethylhexahydro-4-(5-phenylthieno[3,2-b]pyridin-7-yl)- (9CI)
 MF C21 H24 N4 O S
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[3,2-b]pyridine-3-carbonitrile, 2-[[2-(hexahydro-1H-azepin-1-yl)ethyl]thio]-4,5-dihydro-7-hydroxy-5-oxo- (9CI)
 MF C16 H19 N3 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[3,2-b]pyridine-3-carbonitrile, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI)
 MF C14 H17 N5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[1-[[[(4S,7R)-hexahydro-3-hydroxy-7-methyl-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]cyclohexyl]-3-methyl- (9CI)
 MF C28 H35 N5 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(4S,7R)-hexahydro-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-3-methyl- (9CI)
 MF C27 H33 N5 O6 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN


IN 1H-Azepin-3-amine, 1-furo[3,2-b]pyridin-6-ylhexahydro-N-methyl-, (3R)-
(9CI)
MF C14 H19 N3 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[3,2-b]pyridine, 7-(hexahydro-1H-1,4-diazepin-1-yl)-5-phenyl-,
dihydrochloride (9CI)
MF C18 H19 N3 S . 2 Cl H



●2 HCl

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[3,2-b]pyridine, 1-[(1S)-1-[(hexahydro-1H-azepin-1-yl)methyl]propyl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethyl-
(9CI)
MF C27 H34 F3 N3 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(4R)-hexahydro-1-[(1-oxido-2-pyridinyl)sulfonyl]-3-oxo-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]- (9CI)

MF C25 H29 N5 O7 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(3S,4S,7R)-hexahydro-3-hydroxy-7-methyl-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-3-methyl- (9CI)

MF C27 H35 N5 O6 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1H-Azepin-4-amine, 1-furo[3,2-b]pyridin-6-ylhexahydro-N-methyl-, (4R)-
(9CI)
MF C14 H19 N3 O


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Azepin-3-amine, 1-furo[3,2-b]pyridin-6-ylhexahydro-, (3S)- (9CI)
MF C13 H17 N3 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[3,2-b]pyridine, 3-(4-fluorophenyl)-1-[3-(hexahydro-1H-1,4-diazepin-1-yl)propyl]-2-(4-pyridinyl)- (9CI)
MF C26 H28 F N5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(4S,7R)-hexahydro-7-methyl-1-(4-morpholinylsulfonyl)-3-oxo-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-3-methyl- (9CI)
 MF C26 H37 N5 O7 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(3S,4S,7R)-hexahydro-3-hydroxy-7-methyl-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]- (9CI)
 MF C26 H33 N5 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(4S,7R)-hexahydro-7-methyl-1-[(1-oxido-2-pyridinyl)sulfonyl]-3-oxo-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-3-methyl- (9CI)
 MF C27 H33 N5 O7 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Azepin-4-amine, 1-furo[3,2-b]pyridin-6-ylhexahydro-, (4S)- (9CI)
 MF C13 H17 N3 O

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxamide, N-ethylhexahydro-4-(5-phenylthieno[3,2-b]pyridin-7-yl)-, dihydrochloride (9CI)
 MF C21 H24 N4 O S . 2 Cl H



● 2 HCl


L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzeneacetamide, N-[[[3-fluoro-4-[[2-[(hexahydro-1H-azepin-1-yl)carbonyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]-, monohydrochloride (9CI)
 MF C29 H27 F N4 O3 S2 . Cl H



● HCl

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(4S)-hexahydro-1-[(1-oxido-2-pyridinyl)sulfonyl]-3-oxo-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]- (9CI)
 MF C25 H29 N5 O7 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(3S,4S,7R)-hexahydro-3-hydroxy-7-methyl-1-[(1-oxido-2-pyridinyl)sulfonyl]-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]-3-methyl- (9CI)
 MF C27 H35 N5 O7 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[3,2-b]pyridine-2-carboxamide, N-[(1S)-1-[[[(4S,7R)-hexahydro-7-methyl-3-oxo-1-(2-pyridinylsulfonyl)-1H-azepin-4-yl]amino]carbonyl]-3-methylbutyl]- (9CI)
 MF C26 H31 N5 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Azepin-3-amine, 1-furo[3,2-b]pyridin-6-ylhexahydro-N-methyl-, (3S)- (9CI)
 MF C14 H19 N3 O


Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 39 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[3,2-b]pyridine, 3-(4-fluorophenyl)-1-[3-(hexahydro-1H-1,4-
 diazepin-1-yl)propyl]-2-(4-pyridinyl)-, tris(trifluoroacetate) (9CI)
 MF C26 H28 F N5 . 3 C2 H F3 O2

CM 1




CM 2



ALL ANSWERS HAVE BEEN SCANNED

=> d l1
 L1 HAS NO ANSWERS
 L1 STR



VAR G1=C/N
 VAR G2=O/S/N
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 1 8
 NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

=> s l1 ful
 FULL SEARCH INITIATED 13:26:04 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 167090 TO ITERATE


100.0% PROCESSED 167090 ITERATIONS
 SEARCH TIME: 00.00.01

173 ANSWERS

L3 173 SEA SSS FUL L1

=> d scan


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 4-[6-(hexahydro-1H-1,4-diazepin-1-yl)-5-(1-pyrrolidinyl)pyrazinyl]- (9CI)
 MF C20 H25 N7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):172

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-(hexahydro-4-phenyl-1H-1,4-diazepin-1-yl)-6-methyl- (9CI)
MF C20 H23 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-[4-
[(dimethylamino)carbonyl]phenyl]hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
MF C22 H26 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 4-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-3-amino- (9CI)
MF C15 H19 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(2,3,5,6-tetrafluoro-4-pyridinyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C18 H16 F4 N6 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-[4-(dimethylamino)phenyl]hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C21 H26 N6 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(2-chlorophenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C19 H20 Cl N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetyl-4-[6-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-cyano-2-pyridinyl]hexahydro- (9CI)
 MF C20 H19 Cl N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetylhexahydro-4-[6-(5-methyl-1H-pyrrolo[2,3-
 b]pyridin-3-yl)-2-pyridinyl]- (9CI)
 MF C20 H23 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 2-[6-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-
 yl)propoxy]-5-methoxy-1-methyl-1H-indol-3-yl]- (9CI)
 MF C26 H33 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxylic acid, 4-[3-amino-2-(aminocarbonyl)-4-(3-furanyl)thieno[2,3-b]pyridin-6-yl]hexahydro-, 1,1-dimethylethyl ester (9CI)
 MF C22 H27 N5 O4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxylic acid, 4-[1-[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]-3-azetidiny]hexahydro-, 1,1-dimethylethyl ester (9CI)
 MF C30 H36 F N9 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine, 3-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(1-naphthalenylsulfonyl)- (9CI)
MF C24 H25 N3 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C19 H21 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carbothioic acid, 3-amino-5-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethoxy]-4,6-dimethyl-, O-(1,1-dimethylethyl) ester (9CI)
MF C22 H34 N4 O2 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-[4-[3-(dimethylamino)-3-oxopropyl]phenyl]hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C24 H30 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(1-hydroxyethyl)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C21 H25 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(1,1-dimethylethyl)phenyl]hexahydro-1H-1,4-diazepin-1-yl)- (9CI)
 MF C23 H29 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(phenylmethoxy)phenyl]-1H-1,4-diazepin-1-yl)- (9CI)
 MF C26 H27 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(3-methylphenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H23 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetylhexahydro-4-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]- (9CI)
 MF C18 H20 N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxylic acid, 4-[6-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyridinyl]hexahydro-, ethyl ester (9CI)
 MF C20 H22 Cl N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 3-[2-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-4-pyrimidinyl]- (9CI)
 MF C19 H21 N7 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Cyclohexanecarboxamide, N-[3-[(hexahydro-1H-1,4-diazepin-1-yl)carbonyl]-1H-
 pyrrolo[2,3-b]pyridin-5-yl]- (9CI)
 MF C20 H27 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Propanamide, N-[4-[7-[(2,6-difluorophenyl)methyl]-3-[(hexahydro-1H-azepin-1-yl)methyl]-4,7-dihydro-5-(2-methyl-1-oxopropyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-2-methyl- (9CI)
 MF C35 H39 F2 N3 O3 S
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxylic acid, 6-(hexahydro-1H-azepin-1-yl)-4-(trifluoromethyl)-, methyl ester (9CI)
 MF C16 H17 F3 N2 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[2,3-b]pyridine-2-carboxamide, 3-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-
 MF C15 H18 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Propanediamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N'-
 (hexahydro-1H-azepin-1-yl)- (9CI)
 MF C22 H24 F N5 O3


PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-[4-
 [(dimethylamino) carbonyl]-2-thiazolyl]hexahydro-1H-1,4-diazepin-1-yl]-
 (9CI)
 MF C19 H23 N7 O2 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(2-
 oxopropyl)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C22 H25 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(2-thiazolyl)-
 1H-1,4-diazepin-1-yl]- (9CI)
 MF C16 H18 N6 O S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(4-
 ethoxyphenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C21 H25 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(4-fluoro-3-methylphenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H22 F N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(phenylmethyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H23 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 3-[6-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-2-pyridinyl]- (9CI)
 MF C20 H21 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetylhexahydro-4-[4-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]- (9CI)
 MF C19 H22 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 2-[1-[2-[hexahydro-4-[3-(1-pyrrolidinyl)propyl]-1H-1,4-diazepin-1-yl]ethyl]-5,6-dimethoxy-1H-indol-3-yl]- (9CI)
 MF C31 H42 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine-3-carboxaldehyde, 2-(hexahydro-1H-1,4-diazepin-1-yl)-1-phenyl-, mono(trifluoroacetate) (9CI)
 MF C19 H20 N4 O . C2 H F3 O2


, CM 1



CM 2




L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-(3-aminohexahydro-1H-azepin-1-yl)-4-propyl- (9CI)
 MF C17 H25 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[2,3-b]pyridine-2-carboxamide, 3-[[[2-[(hexahydro-1H-azepin-1-yl)carbonyl]-4-morpholinyl]carbonyl]amino]-6-methyl-
 MF C21 H27 N5 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 4-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-5-(1-pyrrolidinyl)pyrazinyl]-, dihydrochloride (9CI)
 MF C21 H27 N7 . 2 Cl H




●2 HCl

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-[3,4-dihydro-4-(hydroxyimino)-2H-1-benzopyran-7-yl]hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C22 H24 N6 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(3-hydroxypropyl)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C22 H27 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-(hexahydro-1H-1,4-diazepin-1-yl)-, dihydrochloride (9CI)
 MF C13 H17 N5 O S . 2 Cl H




● 2 HCl

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(trifluoromethoxy)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H20 F3 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(4-(methan-
 (methylsulfonyl)phenyl)hexahydro-1H-1,4-diazepin-1-yl)]- (9CI)
 MF C20 H23 N5 O3 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(4-(4-(chlorophenyl)hexahydro-1H-1,4-diazepin-1-yl)]- (9CI)
 MF C19 H20 Cl N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Propanamide, N-[3-[6-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-2-pyridinyl]-
 1H-pyrrolo[2,3-b]pyridin-5-yl]- (9CI)
 MF C22 H26 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-4-[4-(5-methoxy-1H-
 pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]-, propyl ester (9CI)
 MF C21 H26 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 2-[6-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethoxy]-5-methoxy-1-methyl-1H-indol-3-yl]- (9CI)
 MF C25 H31 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxylic acid, 4-[3-amino-2-(aminocarbonyl)-4-(2-furanyl)thieno[2,3-b]pyridin-6-yl]hexahydro-, 1,1-dimethylethyl ester (9CI)
 MF C22 H27 N5 O4 S





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-(4-aminohexahydro-1H-azepin-1-yl)-4-propyl- (9CI)
 MF C17 H25 N5 O S


CN1CCc2c(c1)ccc2C3=CN=C4C(=C3)N(C(=O)S(=O)(=O)c5ccccc5)C=C4

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine-4-carboxamide, N-[4-[5-fluoro-6-(hexahydro-4-
methyl-1H-1,4-diazepin-1-yl)-1H-benzimidazol-2-yl]-9H-fluoren-9-yl]- (9CI)
MF C34 H30 F N7 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzeneacetamide, 3-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]-N-
 [4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-thiazolyl]- (9CI)
 MF C24 H26 N6 O3 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-[4-(2-(dimethylamino)-2-oxoethyl]phenyl]hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C23 H28 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(5-methyl-2-pyridinyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C19 H22 N6 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(1-methylethoxy)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C22 H27 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(3-chlorophenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C19 H20 Cl N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(3-chlorophenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H23 N5 O S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 3-[2-(hexahydro-1H-1,4-diazepin-1-yl)-4-pyrimidinyl]- (9CI)
 MF C16 H18 N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxylic acid, 4-[6-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyridinyl]hexahydro-, methyl ester (9CI)
 MF C19 H20 Cl N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 2-[1-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-5,6-dimethoxy-1H-indol-3-yl]-1-[(4-methylphenyl)sulfonyl]-, trifluoroacetate (9CI)
 MF C33 H39 N5 O4 S . x C2 H F3 O2


CM 1

PAGE 1-A




Me

CM 2




L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Propanamide, N-[3-[(hexahydro-1H-1,4-diazepin-1-yl)carbonyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI)
 MF C18 H25 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-[3-(hexahydro-1H-1,4-diazepin-1-yl)-1-azetidiny]- (9CI)
 MF C25 H28 F N9 O
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 1-[(2,3-dichlorophenyl)sulfonyl]-3-(2,3,6,7-tetrahydro-1-methyl-1H-azepin-4-yl)- (9CI)
 MF C20 H19 Cl2 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C13 H15 Cl N4 O

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, hexahydro-1-[imino[3-[3-(2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]methyl]-4-methyl- (9CI)
 MF C27 H29 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Ethanethioic acid, S-[4-[4-[3-amino-2-(aminocarbonyl)thieno[2,3-b]pyridin-4-yl]hexahydro-1H-1,4-diazepin-1-yl]phenyl] ester (9CI)
 MF C21 H23 N5 O2 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-[(2-methyl-1,3-dioxolan-2-yl)methyl]phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C24 H29 N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(3-pyridinyl)-
 1H-1,4-diazepin-1-yl]- (9CI)
 MF C18 H20 N6 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(4-bromophenyl)hexahydro-
 1H-1,4-diazepin-1-yl]- (9CI)
 MF C19 H20 Br N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(3-methoxyphenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H23 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxylic acid, 4-[3-amino-2-(aminocarbonyl)thieno[2,3-b]pyridin-4-yl]hexahydro-, 1,1-dimethylethyl ester (9CI)
 MF C18 H25 N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 3-[6-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-2-pyridinyl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
 MF C28 H38 N8 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 5-chloro-3-[2-(hexahydro-1H-azepin-1-yl)-4-pyrimidinyl]- (9CI)
 MF C17 H18 Cl N5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine, 2-[1-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethyl]-5,6-dimethoxy-1H-indol-3-yl]- (9CI)
MF C25 H31 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine-3-carboxaldehyde, 2-(hexahydro-1H-1,4-diazepin-1-yl)-1-phenyl- (9CI)
MF C19 H20 N4 O
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 6-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-3-amino-4-propyl- (9CI)
MF C18 H25 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[2,3-b]pyridine-2-carboxamide, 3-[[[3-[(hexahydro-1H-azepin-1-yl)carbonyl]-1-piperidinyl]carbonyl]amino]-6-methyl-
 MF C22 H29 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Pyrazinamine, 3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)- (9CI)
 MF C17 H21 N7




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(6-benzoxazolyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H20 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[3-(2-hydroxyethyl)phenyl]-1H-1,4-diazepin-1-yl- (9CI)
 MF C21 H25 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-(4-pyridinyl)-1H-1,4-diazepin-1-yl- (9CI)
 MF C18 H20 N6 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(3-(trifluoromethyl)phenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H20 F3 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C21 H23 N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(4-nitrophenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C19 H20 N6 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Acetamide, N-[3-[6-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-2-pyridinyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]- (9CI)
 MF C21 H24 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-4-[4-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]-, ethyl ester (9CI)
 MF C20 H24 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, hexahydro-1-[[[5-methoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indol-6-yl]oxy]acetyl]-4-methyl- (9CI)
 MF C25 H29 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-4-propyl- (9CI)

MF C17 H23 N5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-(hexahydro-4-hydroxy-1H-azepin-1-yl)-4-propyl- (9CI)
MF C17 H24 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine, 3-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(phenylsulfonyl)- (9CI)
MF C20 H23 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine, 4-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-5-(1-pyrrolidinyl)pyrazinyl]- (9CI)
MF C21 H27 N7

CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
L3 173 ANSWERS   REGISTRY   COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-(hexahydro-1H-1,4-diazepin-
MF 1-yl)- (9CI)
CI C13, H17 N5 O S
   COM
```




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(4-morpholinylcarbonyl)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
MF C24 H28 N6 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(6-chloro-3-pyridazinyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C17 H18 Cl N7 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(4-methyl-3-nitrophenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H22 N6 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(4-methylphenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H23 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(trifluoromethyl)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H20 F3 N5 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetylhexahydro-4-[6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]- (9CI)
 MF C18 H20 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Azepine, 1-[[3-[6-[(3R,5S)-4-acetyl-3,5-dimethyl-1-piperazinyl]-2-pyridinyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]carbonyl]hexahydro-, rel- (9CI)
 MF C27 H34 N6 O2


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 2-[1-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-5,6-dimethoxy-1H-indol-3-yl]-1-[(4-methylphenyl)sulfonyl]-
 (9CI)
 MF C33 H39 N5 O4 S
 CI COM

PAGE 1-A




PAGE 2-A

Me


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-(hexahydro-1H-azepin-1-yl)-
4-(3-piperidinyl)- (9CI)
MF C19 H27 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Azepine, 1-[(3-amino-4,6-dimethylthieno[2,3-b]pyridin-2-
yl)carbonyl]hexahydro- (9CI)
MF C16 H21 N3 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine, 3-[hexahydro-1-(2-phenylethyl)-1H-azepin-4-yl]-
1-(1-naphthalenylsulfonyl)- (9CI)
MF C31 H31 N3 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C19 H20 Cl N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Phenol, 2-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-4-[3-(2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]- (9CI)
 MF C27 H30 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Thieno[2,3-b]pyridine-2-carboxamide, 4-[4-(5-acetyl-2-pyridinyl)hexahydro-
1H-1,4-diazepin-1-yl]-3-amino- (9CI)
MF C20 H22 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(1-oxopropyl)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
MF C22 H25 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 4-[4-(4-acetylphenyl)hexahydro-1H-1,4-diazepin-1-yl]-3-amino- (9CI)
MF C21 H23 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(3-chloro-4-fluorophenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C19 H19 Cl F N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(2-methoxyphenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H23 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-(hexahydro-1H-azepin-1-yl)-
 (9CI)
 MF C14 H18 N4 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 3-[6-(4-acetylhexahydro-1H-1,4-
 diazepin-1-yl)-2-pyridinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI)
 MF C26 H33 N7 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetyl-4-[4-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]hexahydro- (9CI)
 MF C18 H19 Cl N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Hexanamide, 2-ethyl-N-[3-[(hexahydro-1H-1,4-diazepin-1-yl)carbonyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]- (9CI)
 MF C21 H31 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Azepine, 1-[[3-amino-6-(4-chlorophenyl)-4-(trifluoromethyl)thieno[2,3-b]pyridin-2-yl]carbonyl]hexahydro- (9CI)
 MF C21 H19 Cl F3 N3 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-4-propyl- (9CI)
 MF C17 H25 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Furo[2,3-b]pyridine-2-carboxamide, 3-[[[3-[(hexahydro-1H-azepin-1-yl)carbonyl]-1-piperidiny]carbonyl]amino]-
 MF C21 H27 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C22 H28 N4 O S




L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(2,3-dihydro-2-methyl-1-oxo-1H-isoindol-5-yl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C22 H24 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(2-methoxyethyl)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C22 H27 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(2-pyridinyl)-
1H-1,4-diazepin-1-yl]- (9CI)
MF C18 H20 N6 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(3,4-
difluorophenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
MF C19 H19 F2 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(3-fluoro-4-methylphenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H22 F N5 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(4-methoxyphenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H23 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, N-[3-[6-(4-acetylhexahydro-1H-1,4-diazepin-1-yl)-2-

pyridinyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]- (9CI)
 MF C22 H24 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-(ethylsulfonyl)hexahydro-4-[4-(5-methoxy-1H-
 pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]- (9CI)
 MF C19 H24 N6 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 2-[1-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-
 yl)propyl]-5,6-dimethoxy-1H-indol-3-yl]-, trifluoroacetate (9CI)
 MF C26 H33 N5 O2 . x C2 H F3 O2


CM 1



CM 2




L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 3-[4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl]-5-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-pyridinyl]- (9CI)
 MF C26 H24 F2 N8




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-4-propyl- (9CI)
 MF C16 H21 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-pyrrolo[2,3-b]pyridin-1-yl]acetyl]hexahydro-4-methyl-(9CI)
 MF C24 H25 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-4-[3-(1-pyrrolidinyl)-6-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrazinyl]-, 1,1-dimethylethyl ester (9CI)
 MF C25 H33 N7 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-[4-
 [(dimethylamino)carbonyl]phenyl]hexahydro-1H-1,4-diazepin-1-yl]-6-methyl-
 (9CI)
 MF C23 H28 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-[4-(1-
 azetidinyldimethylamino)phenyl]hexahydro-1H-1,4-diazepin-1-yl]-
 (9CI)
 MF C23 H26 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(methylsulfonyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C14 H19 N5 O3 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(4-quinazolinyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C21 H21 N7 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(4-fluorophenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C19 H20 F N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(4-cyanophenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H20 N6 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 4-Pyridinecarbonitrile, 2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-(hexahydro-1H-1,4-diazepin-1-yl)- (9CI)
 MF C18 H17 Cl N6




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetyl-4-[6-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyridinyl]hexahydro- (9CI)
 MF C19 H20 F N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine, 2-[6-[2-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethoxy]ethoxy]-5-methoxy-1-methyl-1H-indol-3-yl]- (9CI)
 MF C27 H35 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1-Piperidinecarboxylic acid, 3-[3-amino-2-(aminocarbonyl)-6-(hexahydro-1H-azepin-1-yl)thieno[2,3-b]pyridin-4-yl]-, 1,1-dimethylethyl ester (9CI)
 MF C24 H35 N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-[3-(hexahydro-1H-1,4-diazepin-1-yl)-1-azetidiny]-, hydrochloride (9CI)
MF C25 H28 F N9 O . x Cl H



● x HCl


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine, 1-(8-quinolinylsulfonyl)-3-(2,3,6,7-tetrahydro-1-methyl-1H-azepin-4-yl)- (9CI)
MF C23 H22 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN INDEX NAME NOT YET ASSIGNED
MF C20 H20 N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Phenol, 2-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-5-[3-(2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]- (9CI)
MF C27 H30 N4 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-[4-[2-(dimethylamino)ethyl]phenyl]hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
MF C23 H30 N6 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-[1-(hydroxyimino)ethyl]phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C21 H24 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(4-ethylphenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C21 H25 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(3-nitrophenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C19 H20 N6 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(methylsulfinyl)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H23 N5 O2 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetyl-4-[4-(5-cyano-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]hexahydro- (9CI)
 MF C19 H19 N7 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetylhexahydro-4-[6-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyridinyl]- (9CI)
 MF C20 H23 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, 1-acetylhexahydro-4-[4-[5-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-2-pyrimidinyl]- (9CI)
 MF C23 H23 N7 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzamide, N-[3-[(hexahydro-1H-1,4-diazepin-1-yl)carbonyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2-methoxy- (9CI)
 MF C21 H23 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide, 6-chloro-N-[(1S)-1-[(4-fluorophenyl)methyl]-2-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-2-oxoethyl]- (9CI)
 MF C22 H21 Cl F N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-(hexahydro-1H-1,4-diazepin-1-yl)-4-propyl- (9CI)
MF C16 H23 N5 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Furo[2,3-b]pyridine-2-carboxamide, 3-[[[(3R)-3-(hexahydro-1H-azepin-1-yl)-1-pyrrolidiny]carbonyl]amino]-
MF C19 H25 N5 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C23 H30 N4 O S




L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 4-[4-(4-acetyl-2-thiazolyl)hexahydro-
1H-1,4-diazepin-1-yl]-3-amino- (9CI)
MF C18 H20 N6 O2 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-[4-(2-
hydroxyethyl)phenyl]-1H-1,4-diazepin-1-yl]- (9CI)
MF C21 H25 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(6-methoxy-3-pyridinyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C19 H22 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[4-(3,4-dimethylphenyl)hexahydro-1H-1,4-diazepin-1-yl]- (9CI)
 MF C21 H25 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-[hexahydro-4-(2-methylphenyl)-1H-1,4-diazepin-1-yl]- (9CI)
 MF C20 H23 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-4-(hexahydro-4-phenyl-1H-1,4-diazepin-1-yl)- (9CI)
 MF C19 H21 N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, N-[3-[6-[4-(cyanoacetyl)hexahydro-1H-1,4-diazepin-1-yl]-2-pyridinyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]- (9CI)
 MF C23 H23 N7 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-1,4-Diazepine, hexahydro-1-[4-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinyl]-4-(methylsulfonyl)- (9CI)
 MF C18 H22 N6 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine, 2-[1-[3-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)propyl]-5,6-dimethoxy-1H-indol-3-yl]- (9CI)
MF C26 H33 N5 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-1,4-Diazepine-1-carboxylic acid, 4-(3-formyl-1-phenyl-1H-pyrrolo[2,3-b]pyridin-2-yl)hexahydro-, 1,1-dimethylethyl ester (9CI)
MF C24 H28 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-[4-(aminocarbonyl)hexahydro-1H-1,4-diazepin-1-yl]-4-propyl- (9CI)
MF C17 H24 N6 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 173 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Propanamide, N-[4-{7-[(2,6-difluorophenyl)methyl]-3-[(hexahydro-1H-azepin-1-yl)methyl]-4,7-dihydro-5-(2-methyl-1-oxopropyl)-4-oxothieno[2,3-b]pyridin-2-yl}phenyl]-2-methyl-, monohydrobromide (9CI)
 MF C35 H39 F2 N3 O3 S . Br H



● HBr

ALL ANSWERS HAVE BEEN SCANNED